Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich's Ataxia
Shots:
- Regenxbio to receive up front- development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio's NAV AAV9 vector to develop & commercialize gene therapies for Friedreich's ataxia
- The focus of the agreement is to strengthen Regenxbio’s intellectual property portfolio and the potential of NAV AAV9 to treat systemic and CNS manifestations of movement disorders
- Regenxbio’s NAV technology platform is an AAV gene delivery platform consisting of 100+ AAV vectors including AAV7- AAV8- AAV9 and AAVrh10 applicable for multiple therapeutic areas
Click here to read full press release/ article | Ref: Regenxbio | Image: Pharmaceutical Technology
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
